Zafrens uses nanofabrication technology to analyze and manipulate cells for drug discovery, integrating multiple disciplines to advance cellular analysis and drug development.

Zafrens

Zafrens | 2,161 followers on LinkedIn. Opening doors to new insights at the interface of biology, chemistry and engineering | Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Drug Hunter and Informatics Expert

Peter Nestler

Venture investor, Harvard professor, entrepreneur

Wasim Malik

Director, Software & Analytics at Zafrens

Steven Brown

Cofounder/Executive Director

Ravi Ramenani

"We think [this approach] to drug discovery and analysis where we miniaturize everything - we do high throughput experiments, but also high resolution experiments - will reveal insights that will allow us to try to democratize and make drug discovery simpler and cheaper" Swamy Vijayan, Founder & CEO Zafrens on Bio_Unlock Episode #002: The Future of Drug Discovery. Watch the full conversation here: https://lnkd.in/dXmDRds6 (or wherever you get your podcasts)

BlueYard Capital

Our CEO, Kandaswamy (Swamy) Vijayan recently joined a podcast Bio_Unlock hosted by BlueYard Capital , alongside Elliot Hershberg , author of the popular newsletter "Century of Biology". Swamy discussed his interdisciplinary approach that merges biology, chemistry, and engineering to understand and manipulate cell states. By miniaturizing experiments and screening at ultra-high throughput, Zafrens is challenging traditional drug discovery methods, enabling the study of thousands of cells simultaneously. Elliot shared insights into the evolution of biotech towards "tech bio," emphasizing the importance of engineering disciplines in revolutionizing biological research. They discussed the transformative potential of AI and machine learning in analyzing vast datasets and guiding experimental design. Thanks to Elliot, Anastasia, and BlueYard Capital for the insightful discussion! 🎙️ #Immunotherapy #Innovation #startup Direct link here: https://lnkd.in/dXmDRds6

We are excited to announce that our CEO Kandaswamy (Swamy) Vijayan will be joining a panel discussion at the Precision Medicine World Conference #PMWC24 next week! Register for the conference here: https://lnkd.in/gM_Xxdi7 Follow our page for future updates at Zafrens Are you interested in learning more about Zafrens or our recently launched Ultra High-Throughput Functional Genomics "Z-Screen" Platform? Leave a message at hello@zafrens.com PMWC - Precision Medicine World Conference , Tal Behar , #PMWC24

Thank you to Genetic Engineering & Biotechnology News (GEN) for speaking with our CEO Swamy Vijayan about Zafrens' $23M financing, as well as our partnering and growth plans! Please reach out to learn more about our exciting work to compress early drug discovery at a fraction of traditional costs by using 200,000 microwell arrays in place of 96 well plates. #drugdiscovery#pharma#biotech#financing#TCR#smallmolecule#bispecific#antibody#biologics#CAR-T#cell#therapy https://lnkd.in/db-Sg5m9

Hello, world! Happy to announce our financing and emergence from stealth. Please reach out if you feel we can work together!

Metric
Company Name	Zafrens
Symbol
MSH ID	COM:ZAFRENS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	zafrens.com
LinkedIn	zafrens
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.90K
Web Traffic Growth	-0.93
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ZAFR

COM:ZAFRENS

Zafrens

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue